Onco-Innovations Signs LOI to Advance ONC010 Development, Appoints VP of Corporate Finance

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced it has entered into a non-binding letter of intent with Nanosoft Polymers as an initial step toward negotiating a services agreement supporting development of its exclusively licensed PNKP inhibitor technology, ONC010. The proposed collaboration would focus on polymer process development, analytical characterization, formulation optimization and manufacturing planning activities designed to support future clinical and regulatory development of the oncology candidate.

The company also appointed Dave Antony as vice president of corporate finance. Antony brings more than 35 years of experience in financial planning, reporting, corporate governance and public company advisory services, including leadership roles with TSX Venture Exchange advisory committees. Onco said his background in capital markets and corporate finance is expected to support the company’s oncology-focused growth strategy and ongoing engagement with investors and other stakeholders.

This development is significant as it marks a concrete step forward in advancing ONC010, a promising cancer treatment targeting solid tumors through PNKP inhibition. The partnership with Nanosoft Polymers aims to address key formulation and manufacturing challenges, which are critical for moving the candidate toward clinical trials. Additionally, the appointment of Dave Antony strengthens the company’s financial leadership, potentially enhancing its ability to secure funding and navigate the complexities of drug development.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. It has secured an exclusive worldwide license to patented technology that targets solid tumours. For more information, visit https://oncoinnovations.com/.

This announcement underscores the company's commitment to advancing its pipeline and may attract investor attention as it progresses toward clinical development. The LOI with Nanosoft Polymers and the new VP appointment together signal a strategic push to bring ONC010 closer to the clinic, which could have implications for patients with solid tumors and for the broader oncology landscape.